Aptevo Therapeutics And Alligator Bioscience's Bispecific Antibody ALG.APV-527 Meets Key Endpoints In Phase 1 Solid Tumor Trial; Shows Favorable Safety And Immune Activation With Stable Disease In Colon And Breast Cancer Patients
Aptevo Therapeutics And Alligator Bioscience's Bispecific Antibody ALG.APV-527 Meets Key Endpoints In Phase 1 Solid Tumor Trial; Shows Favorable Safety And Immune Activation With Stable Disease In Colon And Breast Cancer Patients
aptevo therapeutics和Alligator Bioscience的雙特異性抗體ALG.APV-527在1期實體瘤試驗中達到關鍵終點；在結腸癌和乳腺癌患者中顯示出有利的安全性和免疫激活，並伴有穩定疾病。
Aptevo Therapeutics And Alligator Bioscience's Bispecific Antibody ALG.APV-527 Meets Key Endpoints In Phase 1 Solid Tumor Trial; Shows Favorable Safety And Immune Activation With Stable Disease In Colon And Breast Cancer Patients
aptevo therapeutics和Alligator Bioscience的雙特異性抗體ALG.APV-527在1期實體瘤試驗中達到關鍵終點；在結腸癌和乳腺癌患者中顯示出有利的安全性和免疫激活，並伴有穩定疾病。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間